Fischer Medical Ventures Limited disclosed that its wholly owned material subsidiaries declared dividends for the financial year ended March 31, 2026. The combined domestic dividend payout from Time Medical International Ventures (India) Private Limited and FlynnCare Health Innovations Private Limited totals ₹16.5 crore.

The disclosures were made under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The filings highlight significant cash distributions from key operating units to the parent company.

Subsidiary dividend details

Time Medical International Ventures (India) Private Limited declared a dividend of ₹6.5 crore at its Annual General Meeting held on September 28, 2026. This payout relates to the financial year ended March 31, 2026.

FlynnCare Health Innovations Private Limited also held its Annual General Meeting on September 28, 2026, declaring a dividend of ₹10 crore for the same fiscal period. This represents the largest single domestic dividend contribution among the disclosed subsidiaries.

FMV Global Innovation Pte Limited, a Singapore-based subsidiary, approved an interim dividend of $1.1 million at its Board meeting on September 21, 2026. This declaration is for the year ended March 31, 2027.

What the numbers show

The aggregate dividend inflow to Fischer Medical Ventures comprises ₹16.5 crore from Indian entities and $1.1 million from the global entity. The timing of the declarations indicates that the parent company will receive these funds shortly after the respective AGMs and board meetings. The FY27 interim dividend from FMV Global suggests a forward-looking cash distribution strategy for the international arm, distinct from the retrospective FY26 payouts by the Indian subsidiaries.

Fischer Medical Ventures has approved an aggregate investment of ₹50 crore to participate in the rights issues of three of its wholly owned material subsidiaries. The board decision, taken on September 24, 2026, strengthens the capital base of entities operating in medical imaging, digital healthcare, and global medical device distribution.

Investment breakdown by subsidiary

The company will subscribe to equity shares offered by Time Medical International Ventures (India) Private Limited, FlynnCare Health Innovations Private Limited, and FMV Global Innovation Pte. Ltd. The allocation reflects the specific capital requirements and valuation of each entity.

Subsidiary profiles and financials

Time Medical International Ventures (India) Private Limited operates in the medical diagnostic imaging sector, manufacturing MRI systems at its Visakhapatnam facility. The company reported a turnover of ₹5,500.50 lakh for FY26, down from ₹8,273.58 lakh in FY25.

FlynnCare Health Innovations Private Limited focuses on digital healthcare solutions, including a Digital Hospital platform and community care services. Incorporated in July 2024, it recorded a turnover of ₹8,629.26 lakh in FY26, a significant increase from ₹2,742.46 lakh in FY25.

FMV Global Innovation Pte. Ltd., incorporated in Singapore in July 2024, handles wholesale marketing and sale of medical devices globally. It reported a turnover of S$22,808,941 for FY26, with no revenue in FY25.

Regulatory and transaction details

All three entities are classified as material unlisted subsidiaries under Regulation 24(1) of SEBI (LODR) Regulations, 2015. The transactions are related party deals conducted at arm's length, supported by valuation reports from registered valuers. The consideration is entirely cash-based.

What the numbers show

The investment distribution reveals a strategic tilt toward FMV Global Innovation, which receives ₹26 crore, or 52% of the total capital deployed. This is notable given that FMV Global was incorporated only in FY25 and generated S$22.8 million in turnover in its first full year of operations (FY26). In contrast, Time Medical, despite having a longer operational history since 2019 and higher cumulative revenue, receives the smallest share at ₹11.5 crore. This suggests Fischer Medical Ventures is prioritizing the rapid scaling of its international distribution arm over stabilizing its domestic imaging manufacturing unit.